Metabolic Profiling of Acute Myocardial Injury in Humans

人类急性心肌损伤的代谢分析

• 批准号: 7916834
• 负责人: Gregory Dyer Lewis
• 金额: $ 14.24万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-22 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7916834
• 关键词: Accident and Emergency department; Acute; Award; Biochemical; Biological; Biological Markers; Blood; Blood Tests; Cardiac; Chest Pain; Clinical; Clinical Investigator; Clinical Research; Collaborations; Complement; Coronary Angiography; Coronary sinus structure; Couples; Data; Development; Diagnosis; Diagnostic; Exercise; Exercise stress test; Fostering; Functional disorder; General Hospitals; Heart; Heart Injuries; Heart failure; Hormones; Hour; Human; Hypertrophic Cardiomyopathy; Image; Infarction; Injury; Institutes; Ischemia; K-Series Research Career Programs; Laboratories; Left; Lighting; Liquid Chromatography; Lung; Mass Spectrum Analysis; Massachusetts; Measurement; Measures; Metabolic; Metabolic Marker; Metabolic Pathway; Molecular Weight; Monitor; Myocardial; Myocardial Infarction; Myocardial Ischemia; Myocardial perfusion; Nature; Patients; Performance; Physiology; Plasma; Play; Publishing; Pulmonary Vascular Resistance; Radionuclide Ventriculography; Reporting; Research; Research Methodology; Research Personnel; Right Ventricular Dysfunction; Right Ventricular Function; Role; Sampling; Signal Transduction; Source; Specificity; Technetium Tc 99m Sestamibi; Technology; Testing; Time; Training; Translating; Treadmill Tests; Troponin; Unstable angina; Venous; Ventricular; Ventricular Dysfunction; Whole Organism; abstracting; base; blood pressure regulation; candidate identification; cohort; experience; hemodynamics; improved; liquid chromatography mass spectrometry; metabolomics; novel; novel marker; novel strategies; outcome forecast; programs; response; small molecule; tandem mass spectrometry

DESCRIPTION (provided by applicant): PROJECT SUMMARY: The purpose of this proposal is to foster the candidate's development into a clinical investigator capable of translating metabolic signatures of myocardial ischemia and dysfunction into clinically applicable biomarkers. Dr. Lewis will couple training in mass-spectrometry based small molecule profiling and clinical research methodology through a unique, multi-disciplinary collaboration between the Broad Institute of Harvard & MIT and the Massachusetts General Hospital. There is an unmet clinical need for circulating biomarkers that provide biochemical proof of myocardial ischemia and early (troponin negative) myocardial infarction (Ml). Recent advances in metabolic profiling technologies have enhanced the feasibility of obtaining high throughput "snapshots" of a whole organism's metabolic state. Over the past 2 years, Dr. Lewis has played a central role in establishing a liquid chromatography-mass spectrometry platform to monitor over 400 metabolites per human plasma sample. He proposes to apply this platform to identify and validate metabolic signatures of myocardial ischemia and Ml. Specific Aim 1 will be to identify metabolic changes of Ml and ischemia in two patient cohorts: 1) patients undergoing planned Ml to treat hypertrophic obstructive cardiomyopathy, and 2) patients experiencing myocardial ischemia during exercise treadmill testing (ETT). In both of these cohorts, the controlled nature of the myocardial insult permits samples to be obtained before and after the insult, allowing each patient to serve as his or her own biological control. Coronary sinus sampling will aid in localizing the source of metabolic changes in planned Ml. Specific Aim 2 will be to prospectively validate the diagnostic utility of metabolic markers of myocardial ischemia in a second ETT cohort. Specific Aim 3 will be to validate the diagnostic utility of these novel metabolic biomarkers in patients presenting to the emergency department with chest pain. Specific Aim 4 will be to extend metabolic profiling beyond ischemia to identify metabolic modulators of ventricular dysfunction. The candidate will ultimately integrate training and results from this proposed award with his physiology training to define metabolic signatures of ischemia and heart failure. RELEVANCE: Blood tests that measure markers of heart damage play an important role in making the diagnosis of heart attack and in guiding appropriate treatments. Currently used markers, however, are not detectable in the blood for the first several hours after a heart attack. This proposal outlines a novel strategy to capture rapid changes in circulating metabolites that occur in response to heart injury. These metabolites may serve as new markers of injury to help to guide prompt, appropriate treatments to correct metabolic abnormalities. (End of Abstract)

描述（由申请人提供）：项目总结：本提案的目的是促进候选人发展成为能够将心肌缺血和功能障碍的代谢特征转化为临床适用生物标志物的临床研究者。刘易斯博士将通过哈佛和麻省理工学院布罗德研究所与马萨诸塞州总医院之间独特的多学科合作，将基于质谱的小分子分析和临床研究方法学的培训结合起来。对于提供心肌缺血和早期（肌钙蛋白阴性）心肌梗死（MI）的生化证据的循环生物标志物存在未满足的临床需求。代谢分析技术的最新进展增强了获得整个生物体代谢状态的高通量“快照”的可行性。在过去的2年中，刘易斯博士在建立液相色谱-质谱分析平台以监测每份人血浆样本中的400多种代谢物方面发挥了核心作用。他提出应用该平台来识别和验证心肌缺血和MI的代谢特征。具体目标1将是鉴定两个患者群组中MI和缺血的代谢变化：1）经历计划的MI以治疗肥厚性梗阻性心肌病的患者，和2）在运动平板试验（ETT）期间经历心肌缺血的患者。在这两个队列中，心肌损伤的受控性质允许在损伤之前和之后获得样本，允许每个患者充当他或她自己的生物对照。冠状窦采样将有助于定位计划MI中代谢变化的来源。具体目标2是前瞻性验证心肌缺血代谢标志物在第二个ETT队列中的诊断效用。具体目标3将是验证这些新的代谢生物标志物在急诊科胸痛患者中的诊断效用。具体目标4将是扩大缺血以外的代谢谱，以确定心室功能障碍的代谢调节剂。候选人将最终整合培训和结果，从这个拟议的奖项与他的生理学培训，以确定缺血和心力衰竭的代谢特征。相关性：测量心脏损伤标志物的血液检查在诊断心脏病发作和指导适当治疗方面发挥着重要作用。然而，目前使用的标记物在心脏病发作后的最初几个小时内无法在血液中检测到。该提案概述了一种新的策略，以捕获响应心脏损伤而发生的循环代谢物的快速变化。这些代谢物可以作为新的损伤标志物，帮助指导及时，适当的治疗，以纠正代谢异常。 (End摘要）